Guide · Updated November 2026

Oral Wegovy vs. Compounded Semaglutide vs. Brand Injectable: Three Paths Compared

Oral Wegovy (semaglutide pill, FDA approved December 2025) costs $149 to $299/month self-pay depending on dose, and produced 13.6% weight loss at 64 weeks in the OASIS 4 trial. Compounded semaglutide is not FDA-approved, and the FDA ended the shortage-era allowance for copies in 2025. Brand injectable Wegovy lists at about $1,349, with NovoCare self-pay pricing at $349/month for most doses as of Nov 4, 2026. All three use the same GLP-1 receptor agonist. The best fit depends on insurance, budget, and whether you will take a daily pill or a weekly shot.

In December 2025, the FDA approved the oral pill version of Wegovy, giving semaglutide (the generic molecule inside Ozempic, Wegovy, and Rybelsus) a third delivery format. Now you can get the same GLP-1 receptor agonist as a weekly brand injection, a compounded injection, or a daily oral tablet. This guide compares the three for cash-pay patients in 2026.

I’ve tracked body composition on Mounjaro for the last 14 months with DEXA scans. Most of what I learned about side effects, absorption, and cost translates directly to the semaglutide side of the market. This guide pulls the current prices, the clinical trial data, and the trade-offs I’d weigh if I were starting semaglutide today.

The Three Options at a Glance

Before going deeper on each, here’s the snapshot as of November 4, 2026.

The first thing to notice: all three paths deliver the same molecule, semaglutide, acting on the same GLP-1 receptor. What differs is route, dose, price, legal footing, and how much trial evidence stands behind the exact product.

Option 1: Oral Wegovy (The New Pill)

Oral Wegovy is a daily tablet of semaglutide, the same active molecule Novo Nordisk sells as an injection. Per the Wegovy prescribing information, it starts at 1.5mg and steps up every 30 days to a 25mg maintenance dose. The FDA approved it for weight reduction in December 2025, making it the first oral GLP-1 approved for obesity in the US.

How It Works

Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, blunts appetite signals in the hypothalamus, and raises insulin secretion when blood glucose rises. The pill version uses an absorption enhancer called SNAC to push the molecule across the stomach lining, because peptides usually get destroyed by stomach acid.

The catch: the label says to take it on an empty stomach in the morning with up to four ounces of water, then wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. The label ties these rules to how the tablet is absorbed.

The Clinical Data

The OASIS 4 trial (published in the New England Journal of Medicine in 2025) is the most relevant oral semaglutide trial for weight loss. Participants on the 25 mg oral dose lost an average of 13.6% of body weight at 64 weeks, versus 2.2% on placebo. That’s roughly the same territory as injectable Wegovy in STEP 1 (14.9% at 68 weeks, NEJM February 2021).

GI side effects were common: 74.0% of people on the pill reported one, versus 42.2% on placebo. That is a similar pattern to the injection.

The Price

As of Nov 4, 2026, the NovoCare Wegovy page lists the pill at $149/month for 1.5mg, $199/month for 4mg, and $299/month for 9mg and 25mg. At the maintenance dose, that is $50/month less than the 2.4mg pen at $349/month. Retail pharmacy pricing can differ.

For anyone scared of needles, the pill is a reasonable deal. For anyone already doing well on injections, the savings come with stricter morning rules.

Option 2: Compounded Semaglutide

Compounded semaglutide is semaglutide mixed by a 503A or 503B pharmacy, usually in a multi-dose vial with an insulin syringe. It is not FDA-approved. We did not verify current compounded prices, and they vary by seller.

The Legal Situation in 2026

The FDA declared the semaglutide shortage resolved on February 21, 2025 and removed it from the drug shortage list. The grace periods for 503A pharmacies and 503B outsourcing facilities to keep making copies ended in 2025. A 503A pharmacy can still compound a version only when a prescriber documents a change that makes a significant difference for an identified patient. In April 2026, the FDA proposed excluding semaglutide from the 503B bulks list, saying it did not find a clinical need for outsourcing facilities to compound it.

Some telehealth companies have kept selling compounded semaglutide by adding ingredients such as B12 or glycine to argue a “clinical difference.” The FDA has said a semaglutide and B12 injection within 10% of an approved strength may still count as an essential copy. I’ve covered this in detail in Is Compounded Semaglutide Still Legal in 2026? and Compounded GLP-1 Quality: How to Verify Your Pharmacy. The short answer: the legal ground is much thinner than it was in 2024, and any given compounding pharmacy can stop shipping with little warning.

The Clinical Data (Or Lack of It)

There are no clinical trials on compounded semaglutide specifically. Sellers assume that if the active ingredient matches brand semaglutide and dosing matches STEP 1, outcomes should track the 14.9% benchmark. That assumption has not been tested in a trial.

Quality varies. I’ve seen users report precipitate in vials, inconsistent potency, and bacteriostatic water issues. If you go this route, the compounded pharmacy quality checklist is worth a read before your first purchase.

The Price

We did not verify current compounded semaglutide prices for this update. With the Wegovy pill now starting at $149/month and the pen at $349/month for most doses, the price gap between compounded and brand products is smaller than it was in 2024.

Option 3: Brand Injectable Wegovy

Brand injectable Wegovy is the FDA-approved, Novo Nordisk-manufactured version. Same molecule as Ozempic, different doses. The Wegovy label lists 1.7mg or 2.4mg weekly as the usual maintenance dose for weight, with up to 7.2mg for some patients. Ozempic for diabetes runs 0.5mg to 2mg. I wrote a full comparison of dosing and indication in Ozempic vs Wegovy.

The Price

List price is about $1,349/month, and Novo Nordisk says it will drop to $675 on January 1, 2027. Almost nobody pays list. Real prices:

• NovoCare self-pay (as of Nov 4, 2026): $199/month for new patients’ first two fills of 0.25mg or 0.5mg through December 31, 2026, then $349/month for 1mg to 2.4mg and $399/month for 7.2mg
• With insurance: depends on your plan’s formulary and cost-sharing. Check with your plan before shopping cash prices

At maintenance doses, the 2.4mg pen costs $50/month more than the 25mg pill. If you’re comfortable with a weekly injection, the pen still has the longest track record of the two Novo products.

The Clinical Data

STEP 1 (NEJM, February 2021, n=1,961) remains the foundational trial. 68 weeks of 2.4 mg weekly semaglutide produced 14.9% mean weight loss, versus 2.4% on placebo. About 50.5% of participants lost 15% or more. SURMOUNT-5 (NEJM, May 2025) compared tirzepatide head-to-head against semaglutide over 72 weeks and semaglutide came in at 13.7% mean weight loss versus tirzepatide’s 20.2%.

At the 2.4mg dose and the 25mg pill, the trials point to an average of roughly 14 to 15% weight loss over 12 to 18 months. The Wegovy label now allows up to 7.2mg weekly for some patients who need more, which is not available as a pill.

Head-to-Head: Which Should You Pick?

Let me break this down by the actual questions I’d ask if I were starting today.

If You Have Commercial Insurance With Obesity Coverage

Brand injectable Wegovy or the Wegovy pill, whichever your plan covers. A covered copay often beats cash options. Same molecule, full FDA approval, no legal uncertainty. Check your insurance coverage before shopping cash prices.

If You’re Cash Pay and Cost Is the Main Driver

The cheapest FDA-approved cash path we found is the Wegovy pill, at $149 to $299/month by dose. Compounded semaglutide may still be offered for less, but it is not FDA-approved, copies are now restricted, and there is a real chance your compounding pharmacy shuts down mid-treatment.

If You Want Maximum Clinical Validation at a Cash Price

NovoCare brand Wegovy pen at $349/month for most doses. FDA approved, no legal gray area, priced about 17% above the $299 pill at maintenance, but with the longest safety record behind the dose you’re taking.

If You Hate Needles

Oral Wegovy at $149 to $299/month. The 30-minute fasted window and water-only rule are annoying but real people follow it daily. If a needle is a hard no, the pill removes the main barrier to starting semaglutide at all.

If You Want the Most Weight Loss Possible

None of the above. SURMOUNT-1 (NEJM, 2022, n=2,539) showed tirzepatide at 15 mg produced 20.9% mean weight loss over 72 weeks, compared to semaglutide’s 14 to 15% in STEP 1 and OASIS 4. If weight loss is the single variable that matters, switching to tirzepatide (brand Zepbound or Mounjaro) beats any semaglutide option. I’ve been on Mounjaro myself and my 14-month DEXA results tracked the SURMOUNT numbers.

What About Rybelsus?

A quick note because the question comes up often. Rybelsus is the oral semaglutide pill approved for type 2 diabetes (max dose 14 mg). Oral Wegovy is the same molecule at a higher dose (25 mg) approved for obesity.

Some providers used to prescribe Rybelsus off-label for weight loss. It is not approved for that, and its top dose is much lower. Oral Wegovy at 25 mg is the FDA-approved pill option for obesity. For a deeper comparison of oral vs injection, see Oral vs Injectable GLP-1: Full Comparison and Wegovy Pill vs Injection: Which Is Better?.

Switching Between the Three

Do not switch on your own. The Wegovy label gives switching steps only between two specific doses:

• 2.4mg injection to pill: start the 25mg tablet one week after your last 2.4mg injection.
• 25mg pill to injection: start the 2.4mg weekly injection the day after your last 25mg tablet. If you did not tolerate the 25mg tablet, the label suggests the 1.7mg injection instead.
• Other doses and compounded products: the label gives no conversion. Your prescriber has to plan the switch, which may mean restarting at a lower dose.
• Side effects: Switching can bring back nausea for a while.
• Insurance angle: Some plans cover brand injectable but not oral, or vice versa. Check formulary before switching.

If you’re coming off a GLP-1 or thinking about stopping, the GLP-1 maintenance guide and GLP-1 exit strategy cover what to expect. Regaining weight is the default outcome without a structured plan.

Side Effects Are the Same Across All Three

This part matters. Whether you take semaglutide as a pill, a compounded injection, or a brand injection, the GI side effect profile is driven by the molecule, not the route.

From the adverse reaction table in the Wegovy label for the 2.4mg injection:

• Nausea: 44% (16% on placebo)
• Diarrhea: 30% (16% on placebo)
• Vomiting: 24% (6% on placebo)
• Constipation: 24% (11% on placebo)

In STEP 1, these effects were typically mild to moderate and faded with time. I go through coping strategies in GLP-1 Side Effects: Month by Month and the nausea management guide.

In OASIS 4, 74.0% of people on the 25mg pill reported a GI side effect, versus 42.2% on placebo. Don’t choose the pill expecting fewer side effects.

Muscle Loss Is Also the Same

One more data point worth flagging. A 2025 joint nutrition advisory reports that about 38% of the weight lost in STEP 1 was lean mass (which includes muscle, organs, and water). In a SURMOUNT-1 DXA substudy on tirzepatide, the figure was about 25%. The trials measured different people, so treat this as a rough guide.

Route is unlikely to change this. Daily pill, compounded vial, brand pen. All of them can cost you lean mass, which is why the advisory stresses adequate protein and resistance training. My muscle preservation protocol and protein intake guide are the two pieces I wish I’d read before starting.

Bottom Line

For most cash-pay patients in 2026, the decision narrows fast. As of Nov 4, 2026, the Wegovy pill is the cheapest FDA-approved semaglutide path at $149 to $299/month by dose, if you can follow the morning rules. The NovoCare Wegovy pen at $349/month for most doses is the stable choice with the longest track record. Compounded semaglutide is not FDA-approved, copies have been restricted since 2025, and supply can stop without warning.

Insurance changes everything. If your plan covers brand Wegovy, your copay may beat all three cash options. Check your plan first.

FAQ

Is oral Wegovy as effective as injectable Wegovy?

Close, but slightly behind. Oral Wegovy (25 mg) produced 13.6% mean weight loss in the OASIS 4 trial at 64 weeks. Injectable Wegovy (2.4 mg) produced 14.9% in STEP 1 at 68 weeks. The difference is about 1 to 2 percentage points, within the noise range for trials with different populations. For most patients, effectiveness is similar.

Is compounded semaglutide safe compared to brand Wegovy?

Compounded semaglutide is not FDA-approved, and the FDA does not approve compounded versions for safety or effectiveness before sale. Risk comes from quality control: potency variation, contamination, or mixing errors. There’s no clinical trial data on compounded versions specifically. I’d start with the compounded quality verification guide before picking a provider.

Can I switch from compounded semaglutide to oral Wegovy without stopping?

Only with your prescriber. The Wegovy label gives a switching plan only from the brand 2.4mg injection to the 25mg tablet (start the tablet one week after the last injection). It gives no conversion from other doses or from compounded products, so your prescriber may restart you at a lower tablet dose. Expect some side effects while your body adjusts.

Is oral Wegovy cheaper than injectable Wegovy through NovoCare?

At most doses, yes, as of Nov 4, 2026. The pill is $149/month (1.5mg), $199/month (4mg), and $299/month (9mg and 25mg). The pen is $199/month for new patients’ first two fills of 0.25mg or 0.5mg, then $349/month for 1mg to 2.4mg and $399/month for 7.2mg. At maintenance, the 25mg pill is $50/month less than the 2.4mg pen. NovoCare says pricing will be updated after December 31, 2026.

What if I want more weight loss than semaglutide provides?

Talk to your prescriber about switching molecules. Tirzepatide (brand Zepbound or Mounjaro) produced 20.9% weight loss in SURMOUNT-1 at the 15 mg dose, versus 14.9% for semaglutide 2.4mg in STEP 1. Head-to-head in SURMOUNT-5, tirzepatide produced 20.2% weight loss versus 13.7%, about 47% more in relative terms. If maximum weight loss is the goal and cost isn’t the primary constraint, tirzepatide outperforms all three semaglutide paths.

Related

Guides:

• Cheapest GLP-1 Online · Wegovy Pill vs Injection · Compounded vs Brand-Name GLP-1

Provider Reviews: Ro · Hims · Henry Meds

Compare: All Providers · Best GLP-1 Programs · All Guides

What we checked

This AI-assisted public-source desk check reviewed the Wegovy prescribing information, the STEP 1, OASIS 4, SURMOUNT-1, and SURMOUNT-5 trial publications, the SURMOUNT-1 body composition substudy, a 2025 joint nutrition advisory, NovoCare self-pay pricing, Novo Nordisk’s list price announcement, and FDA compounding statements on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.